Innovation Network Dynamics in the Transformation of Pharmaceutical Enterprises:A Longitudinal Case Study of Company BF's Shift from Generic to Original Drug Development
Using Company BF's transition from generic drug to original new drug development as a longitudinal case study,this research employs innovation theories and methodologies such as enterprise innovation networks and organizational learning balance to compare the innovation networks of original new drug and generic drug development.The data is collected through in-depth interviews,supplemented by academic literature,online information,and internal company documents,and subsequently coded.The innovation networks are compared across three dimensions:network node composition,connection strength,and types of cooperation.The research results indicate that compared to generic drug development,the innovation network for original new drug development is larger,with greater heterogeneity among its members and a more complex structure.During new drug development,the organizational learning balance mode of the focal enterprise is generally intermittent.However,at specific stages,if the focal enterprise and its strong-tie partners are considered equal entities,a dual organizational learning balance mode is formed.This characteristic is more prominent in the development of original new drugs.In the process of new drug development,technological innovation capabilities are provided by strongly connected partners.The focal enterprise enhances its specialization in new drug research and production by focusing on improving its fundamental technological capabilities,thereby ensuring the cyclical evolution of the intermittent organizational learning balance model.
NETL
NSTL
万方数据
